Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nuwiq in previously treated patients with severe hemophilia A
NCT01125813Phase 3Completed
- Sponsor
- Octapharma
- Start
- Jun 2010
- Primary completion
- Jan 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 3, open-label trial of simoctocog alfa in hemophilia A, sponsored by Octapharma. Primary endpoint: Efficacy Assessment After a Total of at Least 50 EDs at 6 months. Started Jun 2010; status: completed.
02
Drugs
simoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT01125813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01125813.